KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) EBIT Margin: 2010-2025

Historic EBIT Margin for Rigel Pharmaceuticals (RIGL) over the last 11 years, with Sep 2025 value amounting to 40.91%.

  • Rigel Pharmaceuticals' EBIT Margin rose 1550.00% to 40.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 42.17%, marking a year-over-year increase of 3614.00%. This contributed to the annual value of 13.49% for FY2024, which is 3103.00% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' EBIT Margin stood at 40.91%, which was down 31.91% from 60.09% recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' EBIT Margin ranged from a high of 60.09% in Q2 2025 and a low of -156.92% during Q1 2022.
  • In the last 3 years, Rigel Pharmaceuticals' EBIT Margin had a median value of 5.49% in 2023 and averaged 7.10%.
  • Data for Rigel Pharmaceuticals' EBIT Margin shows a peak YoY increase of 10,900bps (in 2022) and a maximum YoY decrease of 20,846bps (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Rigel Pharmaceuticals' EBIT Margin stood at -104.94% in 2021, then surged by 10,900bps to 4.05% in 2022, then spiked by 144bps to 5.49% in 2023, then surged by 2,342bps to 28.92% in 2024, then skyrocketed by 1,550bps to 40.91% in 2025.
  • Its EBIT Margin stands at 40.91% for Q3 2025, versus 60.09% for Q2 2025 and 23.95% for Q1 2025.